|
1
|
Hu BT and Chen WZ: MOTS-c improves
osteoporosis by promoting osteogenic differentiation of bone marrow
mesenchymal stem cells via TGF-β/Smad pathway. Eur Rev Med
Pharmacol Sci. 22:7156–7163. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Zhu H, Fang J, Luo X, Yu W, Zhao Y, Li X,
Du J and Lu Y: A survey of bone mineral density of healthy Han
adults in China. Osteoporos Int. 21:765–772. 2010.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Hernlund E, Svedbom A, Ivergård M,
Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B and Kanis
JA: Osteoporosis in the European Union: Medical management,
epidemiology and economic burden. A report prepared in
collaboration with the International Osteoporosis Foundation (IOF)
and the European Federation of Pharmaceutical Industry Associations
(EFPIA). Arch Osteoporos. 8(136)2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Chavassieux P, Portero-Muzy N, Roux JP,
Garnero P and Chapurlat R: Are biochemical markers of bone turnover
representative of bone histomorphometry in 370 postmenopausal
women? J Clin Endocrinol Metab. 100:4662–4668. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Rodan GA and Martin TJ: Therapeutic
approaches to bone diseases. Science. 289:1508–1514.
2000.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Brennan TC, Rizzoli R and Ammann P:
Selective modification of bone quality by PTH, pamidronate, or
raloxifene. J Bone Miner Res. 24:800–808. 2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Lamas AZ, Caliman IF, Dalpiaz PL, de Melo
AF Jr, Abreu GR, Lemos EM, Gouvea SA and Bissoli NS: Comparative
effects of estrogen, raloxifene and tamoxifen on endothelial
dysfunction, inflammatory markers and oxidative stress in
ovariectomized rats. Life Sci. 124:101–109. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ettinger B, Black DM, Mitlak BH,
Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas
PD, Zanchetta JR, Stakkestad J, et al: Multiple Outcomes of
Raloxifene Evaluation (MORE) Investigators: Reduction of vertebral
fracture risk in postmenopausal women with osteoporosis treated
with raloxifene: Results from a 3-year randomized clinical trial.
JAMA. 282:637–645. 1999.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ding J, Ghali O, Lencel P, Broux O,
Chauveau C, Devedjian JC, Hardouin P and Magne D: TNF-alpha and
IL-1beta inhibit RUNX2 and collagen expression but increase
alkaline phosphatase activity and mineralization in human
mesenchymal stem cells. Life Sci. 84:499–504. 2009.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Qiu W, Andersen TE, Bollerslev J, Mandrup
S, Abdallah BM and Kassem M: Patients with high bone mass phenotype
exhibit enhanced osteoblast differentiation and inhibition of
adipogenesis of human mesenchymal stem cells. J Bone Miner Res.
22:1720–1731. 2007.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Mukai T, Otsuka F, Otani H, Yamashita M,
Takasugi K, Inagaki K, Yamamura M and Makino H: TNF-alpha inhibits
BMP-induced osteoblast differentiation through activating SAPK/JNK
signaling. Biochem Biophys Res Commun. 356:1004–1010.
2007.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Chang J, Liu F, Lee M, Wu B, Ting K, Zara
JN, Soo C, Al Hezaimi K, Zou W, Chen X, et al: NF-κB inhibits
osteogenic differentiation of mesenchymal stem cells by promoting
β-catenin degradation. Proc Natl Acad Sci USA. 110:9469–9474.
2013.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Gilbert L, He X, Farmer P, Rubin J, Drissi
H, van Wijnen AJ, Lian JB, Stein GS and Nanes MS: Expression of the
osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A)
is inhibited by tumor necrosis factor-alpha. J Biol Chem.
277:2695–2701. 2002.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kemmler W, Häberle L and von Stengel S:
Effects of exercise on fracture reduction in older adults: A
systematic review and meta-analysis. Osteoporos Int. 24:1937–1950.
2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Harvey N, Dennison E and Cooper C:
Osteoporosis: Impact on health and economics. Nat Rev Rheumatol.
6:99–105. 2010.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Rossouw JE, Anderson GL, Prentice RL,
LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA,
Howard BV, Johnson KC, et al: Writing Group for the Women's Health
Initiative Investigators: Risks and benefits of estrogen plus
progestin in healthy postmenopausal women: Principal results From
the Women's Health Initiative randomized controlled trial. JAMA.
288:321–333. 2002.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Passeri G, Girasole G, Jilka RL and
Manolagas SC: Increased interleukin-6 production by murine bone
marrow and bone cells after estrogen withdrawal. Endocrinology.
133:822–828. 1993.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Vitale RF and Ribeiro FA: The role of
tumor necrosis factor-alpha (TNF-alpha) in bone resorption present
in middle ear cholesteatoma. Rev Bras Otorrinolaringol (Engl Ed).
73:117–121. 2007.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Rayl JM, Wellehan JFX Jr, Bunick D and
Allender MC: Development of reverse-transcriptase quantitative PCR
assays for detection of the cytokines IL-1β, TNF-α, and IL-10 in
chelonians. Cytokine. 119:16–23. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Roggia C, Gao Y, Cenci S, Weitzmann MN,
Toraldo G, Isaia G and Pacifici R: Up-regulation of TNF-producing T
cells in the bone marrow: A key mechanism by which estrogen
deficiency induces bone loss in vivo. Proc Natl Acad Sci USA.
98:13960–13965. 2001.PubMed/NCBI View Article : Google Scholar
|
|
22
|
An J, Tzagarakis-Foster C, Scharschmidt
TC, Lomri N and Leitman DC: Estrogen receptor beta-selective
transcriptional activity and recruitment of coregulators by
phytoestrogens. J Biol Chem. 276:17808–17814. 2001.PubMed/NCBI View Article : Google Scholar
|
